- Generic name
- Eslicarbazepine Acetate
- Strength
- 400 mg
- Dosage form
- Tablet
- Manufactured by
- Square Pharmaceuticals PLC.
Eslicar 400 Tablet
About Eslicar 400 Tablet
Eslicar 400 is a tablet medicine used as add-on therapy for partial seizures in epilepsy. It contains Eslicarbazepine Acetate 400 mg, an anti-epileptic medicine from Square Pharmaceuticals PLC.
What is Eslicar 400 Tablet?
Eslicar 400 is a tablet containing 400 mg of Eslicarbazepine Acetate. It is used as an add-on therapy for partial seizures, with or without secondary generalisation, in people already taking other anti-epileptic medicines. Epilepsy involves excessive electrical activity in the brain. Eslicarbazepine Acetate is converted in the body to eslicarbazepine, which is thought to work by blocking voltage-gated sodium channels, reducing nerve cell activity in the brain. This may help reduce the intensity and number of seizures. The medicine is manufactured by Square Pharmaceuticals PLC and is available in tablet form. Always use it under a doctor's supervision.
Uses of Eslicar 400
Eslicar 400 is indicated as an add-on therapy for partial seizures, with or without secondary generalisation. It is not used alone but is added to existing anti-epileptic treatment when seizures are not fully controlled. The doctor decides if this medicine is suitable based on the type of seizures and the person's response to other treatments. Regular follow-up is needed to assess how well it works and to adjust therapy if required.
How to use Eslicar 400
Eslicar 400 is taken as a tablet, usually once daily. It must be added to existing anticonvulsant therapy, not used as a replacement. The doctor will determine the appropriate dose and schedule for each person, starting with a low dose and adjusting over time based on response. Do not change the dose or stop the medicine without medical advice. If a dose is missed, ask the doctor or pharmacist what to do. Swallow the tablet with water, with or without food, as directed.
Side effects of Eslicar 400
Eslicar 400 may cause side effects related to the central nervous system, such as dizziness and sleepiness, which can increase the risk of accidental injury. It may also be associated with changes in the heart's electrical activity (PR interval prolongation), which could lead to problems like AV block, fainting, or slow heart rate. Not everyone experiences these effects. Tell the doctor if you notice any unusual symptoms, especially dizziness, fainting, or a very slow heartbeat.
Safety and precautions
Before taking Eslicar 400, tell the doctor about any allergy to eslicarbazepine acetate, other carboxamide derivatives (such as carbamazepine or oxcarbazepine), or any ingredients in the tablet. This medicine can cause dizziness and drowsiness, so avoid driving or using machines until you know how it affects you. It may reduce the effectiveness of hormonal contraceptives, so additional non-hormonal contraception is recommended. If you are pregnant, planning pregnancy, or breastfeeding, the doctor should carefully review the treatment. Do not stop the medicine suddenly, as this can increase seizure frequency; it should be withdrawn gradually. Concomitant use with oxcarbazepine is not recommended. Ask your doctor about interactions with other medicines, including carbamazepine, phenytoin, and oral contraceptives.
Frequently asked questions
How should I store Eslicar 400?
Store the tablets in a cool, dry place away from light and moisture. Keep them out of the reach of children. Do not use after the expiry date printed on the pack. If you have any questions about storage, ask your pharmacist.
What is Eslicar 400 used for and what kind of medicine is it?
Eslicar 400 is an anti-epileptic medicine used as add-on therapy for partial seizures, with or without secondary generalisation. It contains Eslicarbazepine Acetate, which is converted in the body to eslicarbazepine and is thought to reduce nerve cell activity in the brain. It is not used alone but added to existing treatment.
What do the tablet form and 400 mg strength mean?
Eslicar 400 comes as a tablet, a solid dosage form to be swallowed. The 400 mg strength means each tablet contains 400 mg of Eslicarbazepine Acetate. The doctor will decide the appropriate dose and course for you; do not adjust it yourself.
Can I stop taking Eslicar 400 suddenly?
No, do not stop this medicine suddenly. As with other anti-epileptic medicines, it should be withdrawn gradually to minimise the potential for increased seizure frequency. Always consult your doctor before making any changes to your treatment.
Indications
Pharmacology
Dosage & Administration
Elderly (over 65 years of age): Caution should be exercised in the treatment of elderly patients as there is limited safety information on the use of Eslicarbazepine acetate in these patients.
Paediatric: The safety and efficacy of Eslicarbazepine acetate below 18 years has not yet been established. No data are available
Interaction
Phenytoin: The dose of Eslicarbazepine acetate may need to be increased and the dose of phenytoin may need to be decreased.
Oral contraceptives: Administration of Eslicarbazepine acetate 1,200 mg once daily to female subjects using a combined oral contraceptive showed an average decrease of 37% and 42% in systemic exposure to levonorgestrel and ethinyloestradiol, respectively. Therefore, women of childbearing potential must use adequate contraception during treatment with Eslicarbazepine acetate.
Simvastatin: The dose of Simvastatin shall be increased if used with Eslicarbazepine.
Contraindications
Side Effects
Pregnancy & Lactation
It is unknown whether Eslicarbazepine acetate is excreted in human breast milk.
Precautions & Warnings
Eslicarbazepine acetate may decrease the effectiveness of hormonal contraceptives. Additional non-hormonal forms of contraception are recommended when using Eslicarbazepine acetate.
As with other anti-epileptic medicinal products, if Eslicarbazepine acetate is to be discontinued it is recommended to withdraw it gradually to minimize the potential of increased seizure frequency.
Concomitant use of Eslicarbazepine acetate with oxcarbazepine is not recommended because this may cause overexposure to the active metabolites.
Rash developed as an adverse reaction in 1.1% of total population treated with Eslicarbazepine acetate in placebo-controlled add-on studies in epileptic patients. If signs or symptoms of hypersensitivity develop, Eslicarbazepine acetate must be discontinued. Hyponatraemia has been reported as an adverse reaction in less than 1% of patients treated with Eslicarbazepine acetate.
Storage Conditions
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.